Table 3. The risk factors for esophageal stricture formation by crude logistic regression before and after propensity score matching.
|
Before matching (n=150) |
After matching (n=74) |
|||||||
|---|---|---|---|---|---|---|---|---|
| n | case (%) | Crude OR (95%CI) | P-value | n | case (%) | Crude OR (95%CI) | P-value | |
| Age | 150 | 37 (24.7) | 0.97 (0.93–1.02) | 0.29 | 74 | 24 (32.4) | 0.95 (0.85–1.06) | 0.37 |
| Gender | ||||||||
| Male | 122 | 30 (24.6) | 1.00 | 59 | 19 (32.2) | 1.00 | ||
| Female | 28 | 7 (25.0) | 1.02 (0.40–2.64) | 0.96 | 15 | 5 (33.3) | 1.54 (0.34–7.08) | 0.58 |
| ASA-PS | ||||||||
| 1 | 19 | 7 (36.8) | 1.00 | 6 | 4 (66.7) | 1.00 | ||
| 2 | 114 | 27 (23.7) | 0.53 (0.19–1.49) | 0.23 | 60 | 19 (31.7) | — | 0.99 |
| 3 | 17 | 3 (17.6) | 0.37 (0.08–1.74) | 0.21 | 8 | 1 (12.5) | — | 0.99 |
| Location | ||||||||
| Ce, Ut | 28 | 11 (39.3) | 1.00 | 13 | 8 (61.5) | 1.00 | ||
| Mt | 71 | 12 (16.9) | 0.31 (0.12–0.84) | 0.02 | 34 | 8 (23.5) | 0.25 (0.03–2.24) | 0.22 |
| Lt, Ae | 51 | 14 (27.5) | 0.59 (0.22–1.55) | 0.28 | 27 | 8 (29.6) | — | 0.99 |
| Endoscopic appearance | ||||||||
| Elevated | 6 | 1 (16.7) | 1.00 | 3 | 1 (33.3) | 1.00 | ||
| Flat | 15 | 2 (13.3) | 0.77 (0.06–10.49) | 0.84 | 6 | 1 (16.7) | — | 0.99 |
| Depressed | 129 | 34 (26.4) | 1.79 (0.20–15.87) | 0.60 | 65 | 22 (33.8) | 0.99 | |
| Tumor diameter (mm) | 150 | 37 (24.7) | 1.04 (1.01–1.07) | <0.01 | 74 | 24 (32.4) | 1.04 (0.96–1.12) | 0.36 |
| Steroid injection | ||||||||
| Yes | 58 | 12 (20.7) | 0.70 (0.32–1.53) | 0.37 | 37 | 7 (18.9) | 1.00 | |
| No | 92 | 25 (27.2) | 1.00 | 37 | 17 (45.9) | 6.00 (1.34–26.8) | 0.02 | |
| Cutting diameter | 150 | 37 (24.7) | 1.02 (0.99–1.05) | 0.07 | 74 | 24 (32.4) | 1.02 (0.97–1.07) | 0.54 |
| Treatment Time | 150 | 37 (24.7) | 1.01 (0.99–1.01) | 0.11 | 74 | 24 (32.4) | 0.99 (0.97–1.03) | 0.93 |
| Circumferential mucosal defect (%) | 150 | 37 (24.7) | 1.12 (1.01–1.17) | <0.01 | 74 | 24 (32.4) | 1.08 (0.98–1.19) | 0.14 |
| Histology | ||||||||
| SCC | 146 | 36 (24.8) | 1.00 | 73 | 24 (32.9) | 1.00 | ||
| Adenocarcinoma | 4 | 1 (25.0) | 1.01 (0.10–10.01) | 0.99 | 1 | 0 (0.0) | — | 0.99 |
| Invaion depth | ||||||||
| EP/LPM | 97 | 24 (24.7) | 1.00 | 45 | 14 (31.1) | 1.00 | ||
| MM/SM1 | 37 | 10 (27.0) | 1.13 (0.48–2.66) | 0.79 | 22 | 8 (36.4) | 1.67 (0.40–6.97) | 0.48 |
| SM2 | 16 | 3 (18.8) | 0.70 (0.18–2.67) | 0.60 | 7 | 2 (28.6) | — | 0.99 |
| Previous CRT | ||||||||
| Yes | 9 | 0 (0.0) | — | — | 3 | 0 (0.0) | — | — |
| No | 141 | 37 (26.2) | 1.00 | 71 | 24 (33.8) | 1.00 | ||
Ae, abdominal esophagus; ASA-PS, American Society of Anaesthesiologist Physical Status classification; Ce, cervical esophagus; CI, confidence interval; CRT, chemoradiotherapy; EP, epithelium; LPM, lamina propria; Lt, lower thoracic esophagus; MM, muscularis mucosa; Mt, middle thoracic esophagus; OR, odds ratio; SCC, squamous cell carcinoma; SM1, submucosal invasion <200 μm; SM2, submucosal invasion ≥200 μm; Ut, upper thoracic esophagus.